Company profile for OncoC4

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.OncoC4 has a pipeline of first-in-class immunotherapy products that are moving through preclinical testing it was founded in 2000 on the scientific discoveries of our founders who have moved our lead product, CD24Fc, from a basic concept into clinical trials fo...
OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.OncoC4 has a pipeline of first-in-class immunotherapy products that are moving through preclinical testing it was founded in 2000 on the scientific discoveries of our founders who have moved our lead product, CD24Fc, from a basic concept into clinical trials for multiple indications. As part of global effort to confront COVID-19, OncoImmune has also completed a Phase III clinical trial, SAC-COVID, which showed that CD24Fc significantly improved clinical recovery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9640 Medical Center Drive Rockville , MD , 20850
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/oncoc4-closes-nearly-50-million-in-series-b-financing-to-advance-multiple-pipeline-candidates-302572998.html

PR NEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/09/08/3146048/0/en/OncoC4-to-Present-Global-Pivotal-Phase-3-Trial-Design-for-Next-Generation-CTLA-4-Antibody-Gotistobart-Monotherapy-Being-Co-Developed-with-BioNTech-in-NSCLC-at-the-IASLC-2025-World-.html

GLOBENEWSWIRE
08 Sep 2025

https://www.globenewswire.com/news-release/2025/08/18/3134994/0/en/OncoC4-Strengthens-Leadership-Team-with-Appointment-of-Shiniu-Wei-as-Chief-Financial-Officer.html

GLOBENEWSWIRE
18 Aug 2025

https://www.globenewswire.com/news-release/2025/07/28/3122423/0/en/OncoC4-Announces-New-Preclinical-Data-Highlighting-ONC-841-a-Novel-SIGLEC-10-Antibody-as-a-Potential-New-Class-of-Therapeutics-for-Alzheimer-s-Disease.html

GLOBENEWSWIRE
28 Jul 2025

https://www.globenewswire.com/news-release/2025/07/22/3119295/0/en/OncoC4-Doses-First-Patient-with-Potential-Best-in-Class-PD-1-VEGF-Bispecific-Antibody-AI-081-in-Phase-2-Portion-of-BIPAVE-001-Trial-for-Advanced-Solid-Tumors-in-US.html

GLOBENEWSWIRE
22 Jul 2025

https://www.globenewswire.com/news-release/2025/07/15/3115510/0/en/OncoC4-to-Present-at-the-2025-Orphan-Drug-Summit-on-Strategies-to-Eliminate-Anti-Drug-Antibodies-in-Orphan-Therapies.html

GLOBENEWSWIRE
15 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty